Viriom

Viriom Inc. is a development and commercial-stage biotechnology company focused on creating novel and affordable drugs for life-threatening infections such as HIV and HBV. The company holds the global exclusive license for Hoffmann-La Roche's Phase 3 and commercial-stage lead compounds (Elpida / elsulfavirine and VM1500A) and has developed patented drug candidates including VM2500, VM3500 LAI formulations, as well as combinations with cell, vaccine, and antibody therapies for the treatment, prevention, and cure of HIV. Viriom has achieved breakthroughs in global treatments, prevention, and cures for HIV and chronic HBV infections.